What Am I Smoking? – Guide to Cannabis Cannabinoids
| Compound Name | Type of Compound | Medical Properties | Description | Boiling Point (F) | Boiling Point (C) | Melting Point (F) | Melting Point (C) | Concentration (% of dry weight) | Relative Content (%) | Chemical Formula | IUPAC Name |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10-Ethoxy-9-hydroxy-∆-6a-tetrahydrocannabinol | Cannabinoid | - | - | - | - | - | - | - | - | - | |
| 10-Oxo-∆-6a-tetrahydrocannabinol (OTHC) | Cannabinoid | - | - | 639 ± 108 | 337 ± 42 | - | - | - | C18H24O2 | (6aR,10aR)-3-ethyl-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | |
| 3,4,4,6-Tetrahydro-7-hydroxy-α-α-2-trimethyl-9-n-propyl-2,6-methano-2H-1-benzoxoci5-methanol (OH-cis-HHCV) | Cannabinoid | - | - | - | - | - | - | - | - | - | |
| 8,9-Dihydroxy-∆-6a-tetrahydrocannabinol | Cannabinoid | - | - | 806 ± 113 | 430 ± 45 | - | - | - | C21H30O3 | (6aR,8R,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-1,8-diol | |
| Cannabichromanon (CBCN) | Cannabinoid | - | - | - | - | - | - | - | - | - | |
| Cannabichromene (CBC) | Cannabinoid | Anti-inflammatory Antibacterial Antifungal Antidepressant Encourages brain growth | CBC is most frequently found in tropical cannabis varieties. CBC is known to relieve pain, reduce inflammation, inhibit cell growth in tumor/cancer cells, and promote bone growth. The effects of CBC appear to be mediated through non-cannabinoid receptor interactions. | 428 | 220 | - | - | 0.0-0.65% | C21H30O2 | 2-methyl-2-(4-methylpent-3-enyl)-7-pentylchromen-5-ol | |
| Cannabichromenic acid (CBCA) | Cannabinoid | Anti-inflammatory Antibacterial | Cannabichromene acid (CBC-a) is considered to be the fourth key cannabinoid found in the cannabis plant. CBC-a is located in the most abundant levels in tropical marijuana plant strains. However, it can also be found in other strains but not at the same levels. In recent years, specific strains of marijuana have been developed that boast higher than normal levels of CBC-a. Medical marijuana researchers and the pharmaceutical industry have found that strains with higher levels of CBC-a help fight inflammation and feature strong antibacterial properties. | 898 ± 113 | 481 ± 45 | - | - | - | C22H30O4 | 5-hydroxy-2-methyl-2-(4-methylpent-3-enyl)-7-pentylchromene-6-carboxylic acid | |
| Cannabichromevarin (CBCV) | Cannabinoid | Anticonvulsant | Cannabichromevarin (CBCV) is a propyl cannabinoid, which means it has a propyl chain in its molecular structure. Instead of having a pentyl chain like its counterpart, cannabichromene (CBC), it branches off to have a propyl chain. This means it can have similar effects to CBC, but with a few differences we should examine. | 754 ± 113 | 401 ± 45 | - | - | - | C19H26O2 | 2-methyl-2-(4-methylpent-3-enyl)-7-propylchromen-5-ol | |
| Cannabichromevarinic acid (CBCVA) | Cannabinoid | - | - | 853 ± 113 | 456 ± 45 | - | - | - | C20H26O4 | 5-hydroxy-2-methyl-2-(4-methylpent-3-enyl)-7-propylchromene-6-carboxylic acid | |
| Cannabicitran (CBT) | Cannabinoid | - | - | 734 ± 108 | 390 ± 42 | - | - | - | C21H30O2 | (6AR,9R,10AS)-6,6,9-Trimethyl-3-pentyl-6A,7,8,9,10,10A-hexahydro-6H-1,9-epoxybenzo[C]chromene | |
| Cannabicyclol (CBL) | Cannabinoid | - | Cannabicyclol is a degradative product - with exposure to light, cannabichromene converts to CBL. It's medical properties are not known as it appears in such minuscule concentrations in comparison to other cannabinoids. | 720 ± 88 | 382 ± 31 | - | - | - | C21H30O2 | 1,1,3a-Trimethyl-6-pentyl-1a,2,3,3a,8b,8c-hexahydro-1H-4-oxabenzo[f]cyclobuta[cd]inden-8-ol | |
| Cannabicyclolic acid (CBLA) | Cannabinoid | Anti-inflammatory Antitumor | Very little is known about CBL-A, as the plant produces very little of it. Curiously, it is the most stable of the cannabinoid acids to heat, resistant to decarboxylation. As a result it yields very little CBL on heating. Cannabicyclol acid is both anti-inflammatory and anti-tumor. | 804 ± 113 | 429 ± 45 | - | - | - | C22H30O4 | (1aS,3aR,8bR,8cR)-8-Hydroxy-1,1,3a-trimethyl-6-pentyl-1a,2,3,3a,8b,8c-hexahydro-1H-4-oxabenzo[f]cyclobuta[cd]indene-7-carboxylic acid | |
| Cannabicyclovarin (CBLV) | Cannabinoid | - | - | 666 ± 88 | 352 ± 31 | - | - | - | C19H26O2 | (1aS,3aR,8bR,8cR)-1,1,3a-Trimethyl-6-propyl-1a,2,3,3a,8b,8c-hexahydro-1H-4-oxabenzo[f]cyclobuta[cd]inden-8-ol | |
| Cannabidiol (CBD) | Cannabinoid | Anxiolytic Analgesic Antipsychotic Anti-inflammatory Antioxidant Antispasmodic | CBD has tremendous medical potential. This is particularly true when the correct ratio of CBD to THC is applied to treat a particular condition. CBD acts as an antagonist at both the CB1 and CB2 receptors, yet it has a low binding affinity for both. This suggests that CBD’s mechanism of action is mediated by other receptors in the brain and body. | 320 - 356 | 160 - 180 | 144 - 145 | 62 - 63 | 0.1-2.89% | C21H30O2 | 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol | |
| Cannabidiol monomethylether (CBDM) | Cannabinoid | - | - | 784 ± 113 | 418 ± 45 | - | - | - | C22H32O2 | 3-methoxy-2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylphenol | |
| Cannabidiol-C4 (CBD-C4) | Cannabinoid | - | - | - | - | - | - | - | - | - | |
| Cannabidiolic Acid (CBDA) | Cannabinoid | Anti-inflammatory Anti-nausea Antioxidant Painkiller Anti-proliferative Antibacterial/antimicrobial | CBDA, similar to THCA, is the main constituent in cannabis with elevated CBD levels. CBDA selectively inhibits the COX-2 enzyme, contributing to cannabis’ anti-inflammatory effects. | 600 - 988 | 316 - 531 | 266 - 424 | 130 - 218 | - | C22H30O4 | 2,4-dihydroxy-3-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-6-pentylbenzoic acid | |
| Cannabidiorcol (CBD-C1) | Cannabinoid | - | - | 777 ± 113 | 414 ± 45 | - | - | - | C17H22O2 | 5-methyl-2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol | |
| Cannabidivarin (CBDV) | Cannabinoid | Anticonvulsant Bone Stimulant | Like THCV, CBDV differs from CBD only by the substitution of a pentyl (5 carbon) for a propyl (3 carbon) sidechain. Although research on CBDV is still in its initial stages, recent studies have shown promise for its use in the management of epilepsy. This is due to its action at TRPV1 receptors and modulation of gene expression. | 147 - 149 | 64 - 65 | -144.38 | -97.99 | - | C19H26O2 | 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-propylbenzene-1,3-diol | |
| Cannabidivarinic acid (CBDVA) | Cannabinoid | Anti-inflammatory | Cannabidivarinic acid (CBDVA) is a non-psychoactive cannabinoid found in Cannabis that reportedly has anti-inflammatory properties. | 950 ± 122 | 510 ± 50 | - | - | - | C20H26O4 | 2,4-dihydroxy-3-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-6-propylbenzoic acid | |
| Cannabielsoic acid A (CBEA-A) | Cannabinoid | - | These appear to be infrequently identified in natural sources and may be produced by photooxidation from the CBD type, these cannabinoids are all in the (5aS,6S,9R,9aR) configuration and include cannabielsoic acid A (CBEA-C5 A), cannabielsoic acid B (both CBEA-C5 B and CBEA-C3 B), and cannabielsoin (both CBE-C3 and CBE-C5) | 882 ± 113 | 472 ± 45 | - | - | - | C22H30O5 | (5aS,6S,9R,9aR)-1,6-dihydroxy-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5aH-dibenzofuran-2-carboxylic acid | |
| Cannabielsoic acid B (CBEA-B) | Cannabinoid | - | These appear to be infrequently identified in natural sources and may be produced by photooxidation from the CBD type, these cannabinoids are all in the (5aS,6S,9R,9aR) configuration and include cannabielsoic acid A (CBEA-C5 A), cannabielsoic acid B (both CBEA-C5 B and CBEA-C3 B), and cannabielsoin (both CBE-C3 and CBE-C5) | 909 ± 113 | 487 ± 45 | - | - | - | C22H30O5 | (5aS,6S,9R,9aR)-1,6-dihydroxy-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5aH-dibenzofuran-4-carboxylic acid | |
| Cannabielsoin (CBE) | Cannabinoid | - | These appear to be infrequently identified in natural sources and may be produced by photooxidation from the CBD type, these cannabinoids are all in the (5aS,6S,9R,9aR) configuration and include cannabielsoic acid A (CBEA-C5 A), cannabielsoic acid B (both CBEA-C5 B and CBEA-C3 B), and cannabielsoin (both CBE-C3 and CBE-C5) | 799 ± 113 | 426 ± 45 | - | - | - | C21H30O3 | (5aS,6S,9R,9aR)-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5aH-dibenzofuran-1,6-diol | |
| Cannabifuran (CBF) | Cannabinoid | - | - | 705 ± 81 | 374 ± 27 | - | - | - | C21H26O2 | 6-Methyl-3-pentyl-9-propan-2-yldibenzofuran-1-ol | |
| Cannabigerol (CBG) | Cannabinoid | Antifungal Analgesic Antibacterial Anti-Epileptic Anti-inflammatory Anti-Insomnia Anti-Proliferative Bone Stimulant Neurogenic | A non-psychoactive cannabinoid, CBG’s antibacterial effects can alter the overall effects of cannabis. CBG is known to kill or slow bacterial growth, reduce inflammation, (particularly in its acidic CBGA form,) inhibit cell growth in tumor/cancer cells, and promote bone growth. It acts as a low-affinity antagonist at the CB1 receptor. CBG pharmacological activity at the CB2 receptor is currently unknown. | 878 | 470 | 120 - 126 | 49 - 52 | 0.03-1.15% | C21H32O2 | 2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-pentylbenzene-1,3-diol | |
| Cannabigerol monomethylether (CBGM) | Cannabinoid | - | CBGM is a member of the cannabigerol (CBG) cannabinoid group. The cannabinoids in the CBG group have similar molecular structures to CBG, meaning they may have similar properties. Like most other minor cannabinoids, not much research has been conducted about CBGM, but we do know a little bit about it. Cannabis plants from northeast Asia seem to have the highest amount of naturally-occurring CBGM, but they still have a low amount compared to other cannabinoids. Interestingly enough, these same plants have high levels of THC and low levels of CBD. | - | - | - | - | - | - | - | |
| Cannabigerolic acid (CBGA) | Cannabinoid | - | CBGA plays an extremely important role as the parent compound in the maturing cannabis flower and undergoes a number of changes to create THC, CBD, CBC, and CBG. This process, called biosynthesis, starts when compounds in the maturing flower, geranyl pyrophosphate and olivetolic acid, bond together to create CBGA. Next, CBGA is exposed to three different enzymes, with the amount of each enzyme determined by the genetics of the plant. | 997 ± 122 | 536 ± 50 | - | - | - | C22H32O4 | 3-[(2E)-3,7-dimethylocta-2,6-dienyl]-2,4-dihydroxy-6-pentylbenzoic acid | |
| Cannabigerolic acid monomethylether (CBGAM) | Cannabinoid | - | A product of the methoxylation of CBGA and CBGVA. This, however, is not very prominent in the cannabinoid profile. A consistent presence of small amounts of CBGAM is reported in plants from north-eastern Asia | 955 ± 122 | 513 ± 50 | - | - | - | C23H34O4 | 3-[(2E)-3,7-dimethylocta-2,6-dienyl]-2-hydroxy-4-methoxy-6-pentylbenzoic acid | |
| Cannabigerovarin (CBGV) | Cannabinoid | - | CBGV belongs to the cannabigerol-type cannabinoid group. This group of cannabinoids is relatively understudied. | 835 ± 104 | 446 ± 40 | - | - | - | C19H28O2 | 2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-propylbenzene-1,3-diol | |
| Cannabigerovarinic acid (CBGVA) | Cannabinoid | Anti-cancer | CBGVA is a precursor cannabinoid which may undergo its own series of enzymatic reactions to form a different ‘family’ of cannabinoids. Molecular transformations take place in response to environmental or external factors such as heat, UV rays, or exposure to oxygen. Therefore, as a cannabis plant ages, the initial CBGA or CBGVA in the plant will react to form new cannabinoids. | 959 ± 122 | 515 ± 50 | - | - | - | C20H28O4 | 3-[(2E)-3,7-dimethylocta-2,6-dienyl]-2,4-dihydroxy-6-propylbenzoic acid | |
| Cannabinodiol (CBND) | Cannabinoid | - | Cannabinodiol (also known as Cannabidinodiol, CBDL and CBND) is a phytocannabinoid that is present in the plant Cannabis sativa at low concentrations. It is the fully aromatized derivative of cannabidiol (CBD) and can occur as a product of the photochemical conversion of cannabinol (CBN). Cannabinodiol is one of the few cannabinoids to be psychotropic per se, together with tetrahydrocannabinol ( THC ), cannabinol and possibly tetrahydrocannabivarin. | 927 ± 104 | 497 ± 40 | - | - | - | C21H26O2 | 2-(5-methyl-2-prop-1-en-2-ylphenyl)-5-pentylbenzene-1,3-diol | |
| Cannabinodivarin (CBVD) | Cannabinoid | - | - | - | - | - | - | - | - | - | - |
| Cannabinol (CBN) | Cannabinoid | Oxidation breakdown product Sedative Antibiotic Immunosuppressant Anti-inflammatory | CBN is a mildly psychoactive cannabinoid that is produced from the degradation of THC. There is usually very little to no CBN in a fresh plant. CBN acts as a weak agonist at both the CB1 and CB2 receptors, with greater affinity for CB2 receptors than CB1. The degradation of THC into CBN is often described as creating a sedative effect, known as a “couch lock.” | 365 | 185 | 169 - 171 | 76 - 77 | 0.0-1.6% | C21H26O2 | 6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol | |
| Cannabinol methylether (CBNM) | Cannabinoid | - | - | 855 ± 75 | 457 ± 24 | - | - | - | C22H28O2 | 1-methoxy-6,6,9-trimethyl-3-pentylbenzo[c]chromene | |
| Cannabinol-C2 (CBN-C2) | Cannabinoid | - | - | - | - | - | - | - | - | - | - |
| Cannabinol-C4 (CBN-C4) | Cannabinoid | - | - | - | - | - | - | - | - | - | |
| Cannabinolic acid (CBNA) | Cannabinoid | Anti-inflammatory | Cannabinolic acid is the parent compound that decarboxylates into CBN. Curiously, in the plant, very little CBN is derived from CBN-A, and we do not see very much CBN-A in the plant; most CBN being derived from the oxidation of THC.CBN-A is anti-inflammatory, and likely anti-biological. | 982 ± 122 | 528 ± 50 | - | - | - | C22H26O4 | 1-hydroxy-6,6,9-trimethyl-3-pentylbenzo[c]chromene-2-carboxylic acid | |
| Cannabiorcol (CBN-C1) | Cannabinoid | - | - | - | - | - | - | - | - | - | - |
| Cannabiripsol (CBR) | Cannabinoid | - | Cannabiripsol is a recently discovered cannabinoid. Whether Cannabiripsol has therapeutic properties remains to be investigated. | 828 ± 113 | 442 ± 45 | - | - | - | C21H32O4 | (6aR,9S,10S,10aR)-6,6,9-trimethyl-3-pentyl-7,8,10,10a-tetrahydro-6aH-benzo[c]chromene-1,9,10-triol | |
| Cannabitriol (CBT) | Cannabinoid | - | First reported in 2014, CBT has essentially the same basic structure as Tetrahyrocannabinol (THC), which is the main psychoactive compound found in ganja and is primarily responsible for giving the 'high'. It is yet to be seen if Cannabitriol is psychoactive or has any curative powers. | 932 ± 122 | 500 ± 50 | - | - | - | C21H30O4 | 6,6,9-trimethyl-3-pentyl-8,10-dihydro-7H-benzo[c]chromene-1,9,10-triol | |
| Cannabitriolvarin (CBTV) | Cannabinoid | - | - | - | - | - | - | - | - | - | |
| Cannabivarin (CBV) | Cannabinoid | - | Cannabivarin (CBV), also known as cannabivarol, is a non-psychoactive cannabinoid found in minor amounts in the hemp plant Cannabis sativa. It is an analog of cannabinol (CBN) with the side chain shortened by two methylene bridges (-CH2-). CBV is an oxidation product of tetrahydrocannabivarin (THCV, THV). | 849 ± 93 | 454 ± 34 | - | - | - | C19H22O2 | 6,6,9-trimethyl-3-propylbenzo[c]chromen-1-ol | |
| Dehydrocannabifuran (DCBF) | Cannabinoid | - | - | 723 ± 81 | 384 ± 27 | - | - | - | C21H24O2 | 6-Methyl-9-isopropenyl-3-pentyldibenzofuran-1-ol | |
| ∆-7-cis-iso-tetrahydrocannabivarin | Cannabinoid | - | - | - | - | - | - | - | - | - | |
| ∆-8-tetrahydrocannabinol (∆8-THC) | Cannabinoid | Antiemetic Anxiolytic Appetite-stimulating Analgesic Neuroprotective | "∆-8-Tetrahydrocannabinol is an analogue of tetrahydrocannabinol (THC) with antiemetic, anxiolytic, appetite-stimulating, analgesic, and neuroprotective properties. ∆-8-tetrahydrocannabinol (∆-8-THC) binds to the cannabinoid G-protein coupled receptor CB1, which inhibits adenyl cyclase, increases mitogen-activated protein kinase activities, modulates several potassium channel conductances and inhibits N- and P/Q-type Ca2+ channels. This agent exhibits a lower psychotropic potency than ∆-9-tetrahydrocannabinol (∆-9-THC)." | 721 ± 108 | 383 ± 42 | - | - | - | C21H30O2 | 6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | |
| ∆-8-tetrahydrocannabinolic acid (∆8-THCA) | Cannabinoid | - | - | 806 ± 113 | 430 ± 45 | - | - | - | C22H30O4 | (6aR,10aR)-1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid | |
| ∆-9-cis-tetrahydrocannabinol (cis-THC) | Cannabinoid | - | - | 734 ± 108 | 390 ± 42 | - | - | - | C21H30O2 | (6aS,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol | |
| ∆-9-tetrahydrocannabinol (THC) | Cannabinoid | Euphoriant Analgesic Anti-inflammatory Antioxidant Antiemetic | The most abundant cannabinoid present in marijuana, THC is responsible for cannabis’ most well-known psychoactive effects. THC acts as a partial agonist at the CB1 and CB2 receptors. The compound is a mild analgesic, or painkiller, and cellular research has shown that it has antioxidant activity. | 392 | 200 | - | - | 0.1-25% | C21H30O2 | 6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol | |
| ∆-9-tetrahydrocannabinol-C4 (THC-C4) | Cannabinoid | - | Tetrahydrocannabinol-C4, also known as THC-C4 and butyl-THC, is a homologue of tetrahydrocannabinol (THC), the active component of cannabis. They are only different by the pentyl side chain being replaced by a butyl side chain. It is unknown whether THC-C4 is an agonist, partial agonist, or antagonist at the cannabinoid receptors. The propyl analog, THCV, is a cannabinoid receptor type 1 and cannabinoid receptor type 2 antagonist, while THC is a CB1 agonist. THC-C4 has rarely been isolated from cannabis samples, but appears to be less commonly present than THC or THCV. It is metabolized in a similar manner to THC. Similarly to THC, it has 7 double bond isomers and 30 stereoisomers. | 1096 ± 122 | 591 ± 50 | - | - | - | C27H38O8 | 3,4,5-trihydroxy-6-(1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-2-yl)oxane-2-carboxylic acid | |
| ∆-9-tetrahydrocannabinolic acid A (THCA-A) | Cannabinoid | - | ∆9-Tetrahydrocannabinolic acid A (THCA-A) is the non psychoactive precursor of ∆9-Tetrahydrocannabinol (!9-THC) and the main cannabinoid component in fresh hemp material. During the smoking process, only a part of THCA-A is converted into the psychoactive ∆9-THC. | 819 ± 113 | 437 ± 45 | - | - | - | C22H30O4 | 1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid | |
| ∆-9-tetrahydrocannabinolic acid B (THCA-B) | Cannabinoid | - | - | - | - | - | - | - | - | - | |
| ∆-9-tetrahydrocannabinolic acid-C4 (THCA-C4) | Cannabinoid | - | - | - | - | - | - | - | C21H28O4 | - | |
| ∆-9-tetrahydrocannabiorcol (THC-C1) | Cannabinoid | Antinociceptive | ∆-9-tetrahydrocannabiorcol (THC-C1) is a non-electrophilic ∆-9-tetrahydrocannabinol derivative that has been studied for use as a pharmacological strategy for treatment of pain | 619 ± 108 | 326 ± 42 | - | - | - | C17H22O2 | (6aR,10aR)-3,6,6,9-tetramethyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol | |
| ∆-9-tetrahydrocannabiorcolic acid (THCA-C1) | Cannabinoid | - | - | - | - | - | - | - | C18H22O4 | (6AR,10AR)-1-HYDROXY-3,6,6,9-TETRAMETHYL-6A,7,8,10A-TETRAHYDRO-6H-BENZO[C]CHROMENE-4-CARBOXYLIC ACID | |
| ∆-9-Tetrahydrocannabivarin (THCV) | Cannabinoid | Analgesic Anorectic Anti-Emetic Anti-Epileptic Anti-inflammatory Bone Stimulant Euphoriant | THCV is a minor cannabinoid found in only some strains of cannabis. The only structural difference between THCV and THC is the presence of a propyl (3 carbon) group, rather than a pentyl (5 carbon) group, on the molecule. Though this variation may seem subtle, it causes THCV to produce very different effects than THC. These effects include a reduction in panic attacks, suppression of appetite, and the promotion of bone growth. THCV acts as an antagonist at the CB1 receptor and a partial agonist at the CB2 receptor. | 428 | < 220 | - | - | 0.0-1.36% | C19H26O2 | (6aR,10aR)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol | |
| ∆-9-tetrahydrocannabivarinic acid (THCVA) | Cannabinoid | - | - | 828 ± 113 | 442 ± 45 | - | - | - | C19H24O4 | 6H-Dibenzo[b,d]pyran-9-carboxylic acid, 6a,7,8,10a-tetrahydro-1-hydroxy-6,6-dimethyl-3-propyl-, (6aR,10aR)- | |
| Ethoxy-cannabitriolvarin (CBTVE) | Cannabinoid | - | - | - | - | - | - | - | - | - | |
| Tetrahydrocannabinolic Acid (THCA) | Cannabinoid | Analgesic Anti-Emetic Anti-inflammatory Anti-Insomnia Anti-Proliferative Antispasmodic Modulates Immune System Neuroprotective | THCA is the main constituent in raw cannabis. THCA converts to Δ9-THC when burned, vaporized, or heated at a certain temperature. THCA, CBDA, CBGA, and other acidic cannabinoids hold the most COX-1 and COX-2 inhibition, contributing to cannabis’ anti-inflammatory effects. This cannabinoid also acts as an antiproliferative and antispasmodic. | 586 - 914 | 308 - 490 | 333 - 406 | 167 - 208 | - | C22H30O4 | (6aR,10aR)-1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid | |
| Trihydroxy-∆-9-tetrahydrocannabinol (triOH-THC) | Cannabinoid | - | - | - | - | - | - | - | - | - | - |